20493 ⎘
Medicinal preparations containing organic active ingredients Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
Stable pharmaceutical composition of immediate-release glimepiride and extended-release metformin
#302Composition Comprising a Diuretic and/or Cardiac Glycosed for the Treatment of Dna Viral Infections of the Eye
#303A COMPOSITION CONTAINING A THIOUREA DERIVATIVE FOR PREVENTING OR TREATING PRURITIC OR IRRITANT SKIN DISEASES
#304Compounds For The Treatment Of An Acute Injury To The Central Nervous System
#305Pharmaceutical composition
#306Pharmaceutical Compositions and Methods for Effecting Dopamine Release
#307Nanoparticle formation of pharmaceutical ingredients
#308Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
#309Antidiabetic formulation and method
#310Pharmaceutical composition and method for the treatment of diseases using HMG-CoA reductase inhibitors and insulin secretion enhancers or sensitizers
#311Co-therapy for diabetic conditions
#312Compositions comprising balaglitazone and further antidiabetic compounds
#313Use of hydroxylated amino acids for treating diabetes
#314Treatment and Diagnosis of Insulin-Resistant States
#315Methods for treating brain swelling with a compound that blocks a non-selective cation channel
#316Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
#317Modified release, multiple unit drug delivery systems
#318Use of a peptide
#319Use of a peptide
#320Methods for the treatment of insulin resistance and disease states characterized by insulin resistance
#321Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
#322CONTROLLED RELEASE LIPOIC ACID
#323Methods for treating spinal cord injury with a compound that inhibits a NCchannel
#324Antisense modulation of PTP1B expression
#325Methods and reagents for the treatment of metabolic disorders
#326Glp-1 and methods for treating diabetes
#327Controlled release alpha lipoic acid formulation with an inositol compound
#328Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
#329Method of treating the syndrome of coronary heart disease risk factors in humans
#330Pharmaceutical composition containing glimepiride and metformin hydrochloride
#331Monocompartment osmotic controlled drug delivery system
#332Methods for treating neural cell swelling
#333Treatment and diagnosis of insulin-resistant states
#334Coated drug delivery formulations
#335Prophylactic and therapeutic agent of diabetes mellitus
#336Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
#337Controlled release arginine α-ketoglutarate
#338Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
#339Use of (-)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of insulin resistance, Type 2 diabetes and hyperlipidemia
#340Methods of using GST-Omega-2
#341Multi-system therapy for diabetes, the metabolic syndrome and obesity
#342Treatment of diabetes with thiazolidinedione and sulphonylurea
#343Pharmaceutical composition
#344Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type II diabetes mellitus
#345Methods for prevention and treatment of gastrointestinal disorders
#346Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
#347Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
#348Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
#349Methods for treating metabolic disorder
#350Self-nanoemulsifying 3D-printed tablet composition and method of use thereof
#351Sulfonylurea derivatives of oleanolic acid